Double-Target immune cell therapy tested for aggressive blood cancer
NCT ID NCT03455972
Summary
This study tests a two-pronged immune cell therapy for adults with high-risk multiple myeloma, a serious blood cancer. After receiving their own stem cell transplant, patients get specially modified T-cells designed to attack cancer by targeting two proteins (CD19 and BCMA). Researchers want to see if this combined approach is safe and helps control the disease longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND EFFICACY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.